Young-onset multiple system atrophy

Journal of the Neurological Sciences

Volumn 319, Issue 1-2, 2012, Pages 168-170

  Kim, Han Joon ^a   Jeon, Beom S ^a   Lee, Jee Young ^b   Yun, Ji Young ^a   Kim, Young Eun ^a   Paek, Sun Ha ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

Author keywords

Multiple system atrophy; Young onset

Indexed keywords

AMANTADINE; BOTULINUM ANTISERUM; LEVODOPA;

ADULT; ARTICLE; BLEPHAROSPASM; BRAIN DEPTH STIMULATION; CEREBELLUM DISEASE; CLINICAL FEATURE; DISEASE ACTIVITY; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOTOR DYSFUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; SHY DRAGER SYNDROME; YOUNG ONSET SHY DRAGER SYNDROME;

ADULT; AGE OF ONSET; BRAIN; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY;

EID: 84862759366     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.04.016     Document Type: Article

References (12)

1. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670-6.
2. Geser F, Wenning G, Seppi K, Stampfer Kountchev M, Scherfler C, Sawires M, et al. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord 2006;21:179-86.
3. Kim HJ, Jeon BS, Lee JY, Yun JY. Survival of Korean patients with multiple system atrophy. Mov Disord 2011;26:909-12.
4. May S, Gilman S, Sowell B, Thomas R, Stern M, Colcher A, et al. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord 2007;22:2371-7. (Pubitemid 351155983)
5. Schrag A, Wenning GK, Quinn N, Ben-Shlomo Y. Survival in multiple system atrophy. Mov Disord 2008;23:294-6. (Pubitemid 351311566)
6. Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002;125:1070-83. (Pubitemid 34464618)
7. Yabe I, Soma H, Takei A, Fujiki N, Yanagihara T, Sasaki H. MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA. J Neurol Sci 2006;249:115-21. (Pubitemid 44665914)
8. O'Sullivan SS, Massey LA, Williams DR, Silveira-Moriyama L, Kempster PA, Holton JL, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008;131:1362-72.
9. Huang Y, Garrick R, Cook R, O'Sullivan D, Morris J, Halliday GM. Pallidal stimulation reduces treatment induced dyskinesias in "minimal change" multiple system atrophy. Mov Disord 2005;20:1042-7. (Pubitemid 41419524)
10. Lezcano E, Gómez Esteban JC, Zarranz JJ, Alcaraz R, Atares B, Bilbao G, et al. Parkinson's disease like presentation of multiple system atrophy with poor response to STN stimulation: a clinicopathological case report. Mov Disord 2004;19:973-7. (Pubitemid 39199271)
11. Tarsy D, Apetauerova D, Ryan P, Norregaard T. Adverse effects of subthalamic nucleus DBS in a patient with multiple system atrophy. Neurology 2003;61:247-9. (Pubitemid 36875312)
12. WenningG, Ben-Shlomo Y,Hughes A,Daniel S, LeesA,QuinnN.What clinical features aremost useful to distinguish definitemultiple systematrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;68:434-40. (Pubitemid 30248742)